Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cevostamab + iberdomide
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cevostamab + iberdomide is an investigational combination regimen being studied primarily for use in relapsed or refractory multiple myeloma. **Cevostamab** is a bispecific monoclonal antibody that targets CD3 on T cells and Fc receptor-homolog 5 (FcRH5) on myeloma cells, bringing immune cells in proximity to myeloma cells to facilitate their destruction through immunologic cytotoxicity. **Iberdomide** is a small molecule classified as a cereblon E3 ligase modulator (CELMoD), structurally related to immunomodulatory drugs (IMiDs) and functions by recruiting the substrate receptors Ikaros (IKZF1) and Aiolos (IKZF3) for ubiquitin-mediated degradation. This results in anti-neoplastic, immunomodulatory, and pro-apoptotic effects. The combination is under evaluation for safety, tolerability, pharmacokinetics, and efficacy in patients with heavily pretreated multiple myeloma, especially those who have failed standard therapies[1][2][3][4].
02
Targets
CD3 (T-cell surface glycoprotein CD3)CRBN (Cereblon)FCRL5 (Fc receptor-like protein 5)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on cevostamab + iberdomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cevostamab + iberdomide.